UsFDA Guidance: Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to an Ebola Disease Outbreak
- Sharan Murugan
- 48 minutes ago
- 3 min read
Maintaining the safety of the blood supply is a critical public health priority, particularly during outbreaks of emerging infectious diseases. Ebola disease, caused by viruses of the Orthoebolavirus genus, is associated with severe illness and can be transmitted through direct contact with infected body fluids. Although transfusion-transmitted Ebola disease has not been widely documented, the potential risk of transmission through blood and blood components requires appropriate preventive measures.
To address this risk, the U.S. Food and Drug Administration (FDA) published the guidance Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to an Ebola Disease Outbreak. The guidance provides recommendations for blood establishments on donor eligibility assessment, donor deferral, blood product management, and regulatory reporting during an Ebola disease outbreak, helping ensure the continued safety, purity, and availability of blood and blood components.
Donor Education and Eligibility Assessment
The guidance recommends that blood establishments maintain donor educational materials that advise individuals with a history of Ebola disease not to donate blood or blood components. During an Ebola disease outbreak, blood establishments should also update donor history questionnaires to assess potential risk factors identified by the FDA.
These assessments should include a donor's history of Ebola disease, recent residence in or travel to countries experiencing an Ebola outbreak, close contact with individuals confirmed or suspected to have Ebola disease, sexual contact with a person who has recovered from Ebola disease, and any notification from public health authorities regarding possible Ebola exposure.
Donor Deferral Recommendations
To protect the blood supply, the FDA recommends specific donor deferral periods based on an individual's risk of Ebola exposure. Individuals with a history of Ebola disease should be deferred indefinitely from donating blood, except when donating convalescent plasma under appropriate investigational protocols.
Individuals who have recently traveled to or resided in a country experiencing an Ebola outbreak should be deferred for eight weeks after leaving the affected country. The same eight-week deferral period applies to individuals who have had close contact with a confirmed Ebola patient or a person under investigation, those who have had sexual contact with an Ebola disease survivor, and individuals notified by public health authorities of possible Ebola exposure.
Blood Product Management
The guidance provides recommendations for managing blood and blood components collected from donors who are later identified as being at risk for Ebola disease. If blood has been collected from a donor who should have been deferred, blood establishments should quarantine and destroy any undistributed blood and blood components that remain within their expiration period.
If blood products have already been distributed, consignees should be notified so that affected products can be retrieved, quarantined, and destroyed where appropriate. However, the guidance notes that plasma intended for further manufacturing using validated viral inactivation and clearance processes generally does not require retrieval because these manufacturing processes have demonstrated effectiveness against lipid-enveloped viruses such as Ebola.
When a donor is later confirmed to have Ebola disease, blood establishments should immediately notify the FDA and evaluate all blood collected from that donor during the eight weeks before disease onset, as well as any blood collected after symptom onset. Where applicable, recipient physicians should also be informed so that transfusion recipients can be appropriately monitored.
Reporting Biological Product Deviations
If blood establishments distribute blood or blood components collected from donors who were later identified as being at risk for or diagnosed with Ebola disease, the guidance recommends reporting a Biological Product Deviation (BPD). Reports should be submitted as soon as possible and no later than 45 calendar days after obtaining information indicating that a reportable event has occurred.
These reporting requirements help the FDA monitor potential risks to the blood supply and support timely regulatory oversight during public health emergencies.
Collection of Convalescent Plasma
The guidance recognizes ongoing interest in the use of convalescent plasma collected from individuals who have recovered from Ebola disease as a potential treatment during outbreaks. Although convalescent plasma has shown biological potential because survivors develop antibodies against the virus, available clinical evidence has not established its effectiveness.
For this reason, convalescent plasma remains an investigational product. Blood establishments wishing to collect or distribute Ebola convalescent plasma in the United States must do so under an Investigational New Drug (IND) application, while sponsors developing related products or devices must comply with the applicable investigational regulatory requirements.
Implementation of the Guidance
The FDA recommends that blood establishments update donor educational materials within 12 weeks of the guidance issue date. Licensed manufacturers should also report implementation of these changes according to the applicable biologics regulations, including annual reports or prior approval supplements where required.